Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults

Eitemau Tebyg

• Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years: An open-label trial
  gan: Shiramoto, Masanari, et al.
  Cyhoeddwyd: (2014)
• Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: A randomized open-label trial
  gan: Juergens, Christine, et al.
  Cyhoeddwyd: (2014)
• Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
  gan: Cordonnier, Catherine, et al.
  Cyhoeddwyd: (2015)
• Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
  gan: Baxter, Roger, et al.
  Cyhoeddwyd: (2015)
• Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
  gan: Juergens, Christine, et al.
  Cyhoeddwyd: (2018)